ArticleTranslational lung cancer research2025
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic inflammation may reduce the efficacy of immunotherapy. For advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression ≥50% and without driver gene mutations, both immunotherapy monotherapy and combination chemoimmunotherapy are considered standard treatment options; however, it remains unclear which treatment is more appropriate depending on the degree of inflammation. This study investigated the impact of inflammation on the effectiveness of pembrolizumab monotherapy versus combination chemoimmunotherapy. Methods: In this retrospective multicenter cohort study, we included patients with advanced NSCLC from 13 Japanese institutions who received pembrolizumab monotherapy or combination chemoimmunotherapy as first-line treatment between March 2017 and October 2021. The systemic immune-inflammation index (SII) was used as an inflammation marker, with a cutoff value of 1,444 based on previous data. Patients were classified into high (SII ≥1,444) and low (SII <1,444) inflammation groups. Results: This study included 347 patients with advanced NSCLC: 212 (61.1%) in the pembrolizumab group and 135 (38.9%) in the combination chemoimmunotherapy group. In the high inflammation population, there were no significant differences in progression-free survival (PFS) and overall survival (OS) between the pembrolizumab and combination chemoimmunotherapy groups. In the low inflammation population, PFS and OS were significantly improved in the combination chemoimmunotherapy group compared to the pembrolizumab group [median PFS: 8.8 Conclusions: In patients with advanced, driver gene mutation-negative NSCLC, high PD-L1 expression (≥50%), and low systemic inflammation, combination chemoimmunotherapy significantly improved PFS and OS compared to pembrolizumab monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.